Moreover, ADAM17 inhibition may serve as a new indirect avenue to target the oncogenic activities of mutant KRAS in cancers including lung cancer (i.e., LAC), CRC and pancreatic cancer. This evidence concerns the gene ADAM17 and familial pancreatic carcinoma.